ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
EU FRP
Projektnummer
00.0140
Projekttitel
CANCER and MSI: Novel approaches towards the diagnosis and therapy of tumours with microsatellite instability.
Projekttitel Englisch
CANCER and MSI: Novel approaches towards the diagnosis and therapy of tumours with microsatellite instability.

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Schlüsselwörter
-
-
-
Anzeigen
Alternative Projektnummern
-
-
-
Anzeigen
Forschungsprogramme
-
-
-
Anzeigen
Kurzbeschreibung
-
-
-
Anzeigen
Weitere Hinweise und Angaben
-
-
-
Anzeigen
Partner und Internationale Organisationen
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
Datenbankreferenzen
-
-
-
Anzeigen

Erfasste Texte


KategorieText
Schlüsselwörter
(Englisch)
Colon cancer; HNPCC; microsatellite instability; mismatch repair; chemotherapy;
Life Sciences; Medicine; Health; Scientific Research
Alternative Projektnummern
(Englisch)
EU project number: QLG1-CT-2000-01230
Forschungsprogramme
(Englisch)
EU-programme: 5. Frame Research Programme - 1.1.8 Generic R&D activities
Kurzbeschreibung
(Englisch)
See abstract
Weitere Hinweise und Angaben
(Englisch)
Full name of research-institution/enterprise:
Universität Zürich
Institute of Melecular Cancer Research
Partner und Internationale Organisationen
(Englisch)
University of Leiden (NL), Istituto Superiore di Sanita (I), Istituto Dermopatico dell'Immaccolata (I), University of Helsinki (FIN), University of Roskilde (DK), Slovak Academy of Sciences (SK)
Abstract
(Englisch)
A large percentage of tumours from hereditary non-polyposis colon cancer (HNPCC) patients, as well as more than 15% of sporadic colon tumours, display microsatellite instability (MSI) , which has been linked to a defect in mismatch correction (MMR) . Tumour cells with high MSI (MSI-H) differ from other cancer cells: they are largely diploid and the oncogenes and tumour suppressor genes mutated in them are frequently different from those altered in sporadic disease without MSI. We shall compare the response of normal and MSI-H cells to a series of chemotherapeutic and radio-mimetic agents, as well as to ionising and non-ionising radiation. The principal aim of this program is to exploit the identified differences in cancer therapy, by devising ways of selectively killing cells with MSI. The second goal of the study is to use our findings to develop new, facile, diagnostic strategies for the identification of at-risk individuals.
Datenbankreferenzen
(Englisch)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 00.0140